Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Anti-TNF, a magic bullet in cancer immunotherapy?

Montfort A, Dufau C, Colacios C, Andrieu-Abadie N, Levade T, Filleron T, Delord JP, Ayyoub M, Meyer N, Ségui B.

J Immunother Cancer. 2019 Nov 14;7(1):303. doi: 10.1186/s40425-019-0802-y.

PMID:
31727152
2.

Corrigendum: The TNF Paradox in Cancer Progression and Immunotherapy.

Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, Ségui B.

Front Immunol. 2019 Oct 22;10:2515. doi: 10.3389/fimmu.2019.02515. eCollection 2019.

3.

The TNF Paradox in Cancer Progression and Immunotherapy.

Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, Ségui B.

Front Immunol. 2019 Jul 31;10:1818. doi: 10.3389/fimmu.2019.01818. eCollection 2019. No abstract available. Erratum in: Front Immunol. 2019 Oct 22;10:2515.

4.

Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma.

Bilal F, Montfort A, Gilhodes J, Garcia V, Riond J, Carpentier S, Filleron T, Colacios C, Levade T, Daher A, Meyer N, Andrieu-Abadie N, Ségui B.

Front Pharmacol. 2019 Apr 30;10:443. doi: 10.3389/fphar.2019.00443. eCollection 2019.

5.

[Anti-TNFα antibodies in melanoma immunotherapy].

Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, Ségui B.

Med Sci (Paris). 2018 Oct;34(10):788-791. doi: 10.1051/medsci/2018202. Epub 2018 Nov 19. French. No abstract available.

6.

A Natural Variant of the Signaling Molecule Vav1 Enhances Susceptibility to Myasthenia Gravis and Influences the T Cell Receptor Repertoire.

Bernard I, Sacquin A, Kassem S, Benamar M, Colacios C, Gador M, Pérals C, Fazilleau N, Saoudi A.

Front Immunol. 2018 Oct 25;9:2399. doi: 10.3389/fimmu.2018.02399. eCollection 2018.

7.

The costimulatory molecule CD226 signals through VAV1 to amplify TCR signals and promote IL-17 production by CD4+ T cells.

Gaud G, Roncagalli R, Chaoui K, Bernard I, Familiades J, Colacios C, Kassem S, Monsarrat B, Burlet-Schiltz O, de Peredo AG, Malissen B, Saoudi A.

Sci Signal. 2018 Jul 10;11(538). pii: eaar3083. doi: 10.1126/scisignal.aar3083.

PMID:
29991650
8.

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.

Bertrand F, Montfort A, Marcheteau E, Imbert C, Gilhodes J, Filleron T, Rochaix P, Andrieu-Abadie N, Levade T, Meyer N, Colacios C, Ségui B.

Nat Commun. 2017 Dec 22;8(1):2256. doi: 10.1038/s41467-017-02358-7.

9.

S1P: the elixir of life for naive T cells.

Pérès M, Montfort A, Andrieu-Abadie N, Colacios C, Ségui B.

Cell Mol Immunol. 2018 Jul;15(7):657-659. doi: 10.1038/cmi.2017.110. Epub 2017 Oct 30. No abstract available.

10.

Downregulation of sphingosine kinase-1 induces protective tumor immunity by promoting M1 macrophage response in melanoma.

Mrad M, Imbert C, Garcia V, Rambow F, Therville N, Carpentier S, Ségui B, Levade T, Azar R, Marine JC, Diab-Assaf M, Colacios C, Andrieu-Abadie N.

Oncotarget. 2016 Nov 1;7(44):71873-71886. doi: 10.18632/oncotarget.12380.

11.

A Natural Variant of the T Cell Receptor-Signaling Molecule Vav1 Reduces Both Effector T Cell Functions and Susceptibility to Neuroinflammation.

Kassem S, Gaud G, Bernard I, Benamar M, Dejean AS, Liblau R, Fournié GJ, Colacios C, Malissen B, Saoudi A.

PLoS Genet. 2016 Jul 20;12(7):e1006185. doi: 10.1371/journal.pgen.1006185. eCollection 2016 Jul.

12.

Targeting TNF alpha as a novel strategy to enhance CD8+ T cell-dependent immune response in melanoma?

Bertrand F, Rochotte J, Colacios C, Montfort A, Andrieu-Abadie N, Levade T, Benoist H, Ségui B.

Oncoimmunology. 2015 Aug 12;5(1):e1068495. eCollection 2016.

13.

TNF-R1, an immune checkpoint in melanoma?

Bertrand F, Colacios C, Ségui B.

Genes Cancer. 2015 Sep;6(9-10):369-70. No abstract available.

14.

Glucosylceramidases and malignancies in mammals.

Astudillo L, Therville N, Colacios C, Ségui B, Andrieu-Abadie N, Levade T.

Biochimie. 2016 Jun;125:267-80. doi: 10.1016/j.biochi.2015.11.009. Epub 2015 Nov 12. Review.

PMID:
26582417
15.

Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma.

Bertrand F, Rochotte J, Colacios C, Montfort A, Tilkin-Mariamé AF, Touriol C, Rochaix P, Lajoie-Mazenc I, Andrieu-Abadie N, Levade T, Benoist H, Ségui B.

Cancer Res. 2015 Jul 1;75(13):2619-28. doi: 10.1158/0008-5472.CAN-14-2524. Epub 2015 May 14.

16.

Monogenic neurological disorders of sphingolipid metabolism.

Sabourdy F, Astudillo L, Colacios C, Dubot P, Mrad M, Ségui B, Andrieu-Abadie N, Levade T.

Biochim Biophys Acta. 2015 Aug;1851(8):1040-51. doi: 10.1016/j.bbalip.2015.01.010. Epub 2015 Feb 7. Review.

PMID:
25660725
17.

Genetic control of HgCl2-induced IgE and autoimmunity by a 117-kb interval on rat chromosome 9 through CD4 CD45RChigh T cells.

Pedros C, Papapietro O, Colacios C, Casemayou A, Bernard I, Garcia V, Lagrange D, Mariamé B, Andreoletti O, Fournié GJ, Saoudi A.

Genes Immun. 2013 Jun;14(4):258-67. doi: 10.1038/gene.2013.21. Epub 2013 Apr 25.

PMID:
23615071
18.

A spontaneous mutation of the rat Themis gene leads to impaired function of regulatory T cells linked to inflammatory bowel disease.

Chabod M, Pedros C, Lamouroux L, Colacios C, Bernard I, Lagrange D, Balz-Hara D, Mosnier JF, Laboisse C, Vergnolle N, Andreoletti O, Roth MP, Liblau R, Fournié GJ, Saoudi A, Dejean AS.

PLoS Genet. 2012 Jan;8(1):e1002461. doi: 10.1371/journal.pgen.1002461. Epub 2012 Jan 19.

19.

The p.Arg63Trp polymorphism controls Vav1 functions and Foxp3 regulatory T cell development.

Colacios C, Casemayou A, Dejean AS, Gaits-Iacovoni F, Pedros C, Bernard I, Lagrange D, Deckert M, Lamouroux L, Jagodic M, Olsson T, Liblau RS, Fournié GJ, Saoudi A.

J Exp Med. 2011 Oct 24;208(11):2183-91. doi: 10.1084/jem.20102191. Epub 2011 Sep 26.

20.

A role for VAV1 in experimental autoimmune encephalomyelitis and multiple sclerosis.

Jagodic M, Colacios C, Nohra R, Dejean AS, Beyeen AD, Khademi M, Casemayou A, Lamouroux L, Duthoit C, Papapietro O, Sjöholm L, Bernard I, Lagrange D, Dahlman I, Lundmark F, Oturai AB, Soendergaard HB, Kemppinen A, Saarela J, Tienari PJ, Harbo HF, Spurkland A, Ramagopalan SV, Sadovnick DA, Ebers GC, Seddighzadeh M, Klareskog L, Alfredsson L, Padyukov L, Hillert J, Clanet M, Edan G, Fontaine B, Fournié GJ, Kockum I, Saoudi A, Olsson T.

Sci Transl Med. 2009 Dec 9;1(10):10ra21. doi: 10.1126/scitranslmed.3000278.

21.

[The rat Toxo1 locus controls the outcome of the toxoplasmic infection according to a mendelian mode].

Cavaillès P, Bisanz C, Papapietro O, Colacios C, Sergent V, Pipy B, Saoudi A, Cesbron-Delauw MF, Fournié GJ.

Med Sci (Paris). 2006 Aug-Sep;22(8-9):679-80. French. No abstract available.

22.

The rat Toxo1 locus directs toxoplasmosis outcome and controls parasite proliferation and spreading by macrophage-dependent mechanisms.

Cavaillès P, Sergent V, Bisanz C, Papapietro O, Colacios C, Mas M, Subra JF, Lagrange D, Calise M, Appolinaire S, Faraut T, Druet P, Saoudi A, Bessieres MH, Pipy B, Cesbron-Delauw MF, Fournié GJ.

Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):744-9. Epub 2006 Jan 6.

23.

Functional and genetic analysis of two CD8 T cell subsets defined by the level of CD45RC expression in the rat.

Xystrakis E, Cavailles P, Dejean AS, Cautain B, Colacios C, Lagrange D, van de Gaar MJ, Bernard I, Gonzalez-Dunia D, Damoiseaux J, Fournié GJ, Saoudi A.

J Immunol. 2004 Sep 1;173(5):3140-7.

24.

Supplemental Content

Loading ...
Support Center